Johnson & Johnson
Following research that indicates a possible link between gynecomastia and use of Risperdal, a law firm says it is continuing to offer legal consultations to those who developed the condition.
Despite one's best intentions for 2014, there will be days when you feel like you are failing your residents, your coworkers, your family or yourself.
Pharmaceuticals giant Johnson & Johnson and some subsidiaries will pay more than $2.2 billion to settle claims that they inappropriately promoted antipsychotic drugs for use in nursing homes. The agreement also will settle kickback charges related to the nation's largest long-term care pharmacy, Omnicare.
Two big reactions hit me when news of Johnson & Johnson's $2.2 billion Risperdal settlement with the government landed this week. First, J&J probably made a lot more than it's paying out and, second, some individual probably is going to cash a nice paycheck for bringing it all to light.
If unions have their way, nursing homes and other low-wage employers will soon be portrayed as being on the wrong side of the civil rights movement.
In January, Alex Gorsky will take over as the new chairman of Johnson & Johnson. That's because William C. Weldon will be stepping down at the end of the year, according to the firm.
Janssen Pharmaceuticals, a unit of Johnson & Johnson, will pay $181 million to settle charges that it marketed antipsychotic medications for medically unapproved purposes.
Alzheimer's researchers met with disappointment Monday when officials from Pfizer announced that the experimental drug bapineuzumab failed to improve dementia symptoms in a Phase 3 trial.
The battle over antipsychotics use for seniors and their marketing shows no signs of abating. The latest blow is a billion-dollar court decision against a pharmaceutical giant accused of too aggressively pushing the drug Risperdal, which is taken by many seniors with Alzheimer's disease.
Government prosecutors rejected a $1 billion offer by Johnson & Johnson to settle a Risperdal case. Prosecutors alleged the antipsychotic medication was often prescribed off-label to treat aggressive behaviors of elderly nursing home residents with dementia. They are reportedly seeking a settlement closer to $1.4 billion. While doctors may prescribe drugs as they see fit, drug companies can market medications only for uses approved by the Food and Drug Administration.
Government prosecutors rejected a proposed settlement worth roughly $1 billion with pharmaceutical giant Johnson & Johnson over questionable marketing tactics for the antipsychotic Risperdal.
Johnson & Johnson has agreed to pay $158 million to settle a Medicaid fraud lawsuit in Texas. The lawsuit accused J & J subsidiary Janssen Pharmaceuticals of giving state officials kickbacks in exchange for putting the antipsychotic Risperdal on an approved list for Medicaid recipients. The suit also claimed that Janssen marketed the drug as being safe and cost-effective, despite being linked to an increased risk of stroke and death in elderly dementia patients. Risperdal is approved only to treat adult schizophrenia. Johnson & Johnson was recently ordered to pay $327 million in South Carolina and $258 million in Louisiana in similar Rispedal lawsuits.
Johnson & Johnson has agreed to pay $158 million to settle a Medicaid fraud lawsuit. The lawsuit accused J & J subsidiary Janssen Pharmaceuticals of giving state officials kickbacks in exchange for putting the antipsychotic Risperdal on an approved list for Medicaid recipients.